Medical News

Primary Findings From The GLOW Study Signals Positive Momentum In The Development Of Novel Therapeutic Options For Patients With HER2-Negative Locally Advanced Unresectable Or Metastatic Gastric & GEJ Cancers

At the end of 2022, leaders of the Phase 3 clinical trial GLOW shared their positive primary findings. GLOW (NCT03653507) is a global, multicenter,...

Read

Trastuzumab Deruxtecan Meets Objective Response Rate Endpoint in Several Types of HER2-expressing Advanced Solid Tumours

Positive topline results of the ongoing DESTINY-PanTumour02 Phase II trial (NCT04482309) showed that treatment with trastuzumab deruxtecan met the...

Read

The First International Management Guidelines for Early-Onset Colorectal Cancer

This March, the Clinical Gastroenterology and Hepatology journal published the first management guidelines for Early-Onset Colorectal Cancer (eo-CR...

Read

Imfinzi & Imjudo Immunotherapy Drug Combinations Approved in the EU for the Treatment of Advanced Liver Cancer 

The combination of durvalumab (Imfinzi) and tremelimumab (Imjudo) immunotherapies has been approved by the European Commission (EC) for the first-l...

Read

Zolbetuximab Plus Chemotherapy Extends Overall Survival for Patients with Advanced or Metastatic Gastric & Gastro-oesophageal Junction Adenocarcinoma

The Annual American Society of Clinical Oncologists Gastrointestinal Cancers Symposium (ASCO GI) kicked off the year with lots of new data in the f...

Read

DiCE Supports Act4Biosimilars to Increase Patient Access to Biologic Medicines

On 30 January, the Act4Biosimilars initiative hosted a virtual meeting with key stakeholders from across the healthcare space to discuss the Action...

Read

First Immunotherapy Drug Durvalumab Plus Chemotherapy Approved in Europe for Advanced Biliary Cancer

On 21 December the European Commission (EC) approved the use of durvalumab (Imfinzi ®) plus chemotherapy (gemcitabine plus cisplatin) as the first...

Read

The EC Approves Nivolumab Plus Chemotherapy as First Line Treatment for Oesophageal Cancer
Trastuzumab Deruxtecan Approved as Second-line Treatment in Europe For Patients With HER2-positive Advanced Gastric Cancer

On December 19th the European Commission (EC) approved the use of trastuzumab deruxtecan (Enhertu ®) plus chemotherapy (gemcitabine plus cisplatin...

Read

COVID-19 impact on healthcare management of people with chronic diseases

The European Patients’ Forum (EPF) conducted a COVID-19 survey between 18 September to 18 October 2020 (the report is available here).&...

Read

Scientific Update – Study Delivers Promising Results for Genetic Biomarker Test for Stage II Colorectal Cancer cover
Study Delivers Promising Results for Genetic Biomarker Test for Stage II Colorectal Cancer

Sceintific Update – researchers conduct trial to assess if a ctDNA-guided approach could reduce the use of adjuvant chemotherapy in a patient...

Read

In order to facilitate the use of our website, we use cookies.

Please confirm if you accept our tracking cookies. When declining the cookies, you can continue visiting the website without sending data to third party services. Read our complete cookie statement here.